ITCI News and Press, Intra-Cellular Therapies Inc. From 05/01/23

2023-05-01 08:33:59 ET A stronger-than expected earnings season is bolstering belief that an EPS recovery can arrive in the second half of the year, but at the same time leading macro data have slowed, according to Morgan Stanley strategist Mike Wilson. Late last week, concerns about ...

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast...

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...

2023-04-20 13:40:42 ET Morgan Stanley launched its coverage on Intra-Cellular Therapies ( NASDAQ: ITCI ) with an Overweight recommendation, expecting the strong sales momentum for the company’s schizophrenia therapy Caplyta to continue ahead of Phase 3 readouts for additional...

2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer an...

2023-03-29 10:35:42 ET Summary Intra-Cellular Therapies reported positive results from study 403 in MDD patients with mixed features and bipolar disorder patients with mixed features. The results were consistently positive on the primary endpoint - the MADRS score, the secondary e...

2023-03-28 12:27:04 ET Shares of Intra-Cellular Therapeutics (NASDAQ: ITCI) were up 14.8% Tuesday morning after the healthcare company released top-line phase 3 trial information regarding its depression therapy, Caplyta (lumateperone). The drug, administered in a 42-milligram d...

2023-03-28 10:00:38 ET Gainers: Biomea Fusion ( BMEA ) +56% . Oscar Health ( OSCR ) +54% . Viking Therapeutics ( VKTX ) +51% . Intra-Cellular Therapies ( ITCI ) +20% . Guardion Health Sciences ( GHSI ) +17% . Losers...